Premium
THIP: A single‐blind controlled trial in patients with epilepsy
Author(s) -
Petersen Henrik Reeh,
Jensen Inge,
Dam Mogens
Publication year - 1983
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1983.tb04552.x
Subject(s) - concomitant , epilepsy , placebo , anesthesia , medicine , single blind , randomized controlled trial , psychiatry , alternative medicine , pathology
‐ In an early phase‐2 study, THIP (4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin‐3‐ol) was investigated in a single‐blind controlled trial comprising 9 outpatients suffering from epilepsy. THIP was added to the concomitant antiepileptic treatment with increasing doses (15 to 120 mg/day) based on therapeutic effect or side‐effects. The blood levels of concomitant therapy were kept constant. No significant difference was established between the number of seizures during treatment with maximal doses of THIP and placebo. A trend was observed for lower seizure frequency during a period on submaximal dose of THIP.